MetLife Investment Management’s Stemline Therapeutics, Inc. STML Stock Holding History

MetLife Investment Management’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-18,471	Closed	-$89.4K	–	2400
2020 Q1	$89.4K	Hold	18,471	–	–	﹤0.01%	2131
2019 Q4	$196K	Hold	18,471	–	–	﹤0.01%	1983
2019 Q3	$192K	Hold	18,471	–	–	﹤0.01%	1974
2019 Q2	$283K	Hold	18,471	–	–	﹤0.01%	1826
2019 Q1	$237K	Buy	18,471 +6,524	+55%	+$73.8K	﹤0.01%	1890
2018 Q4	$113K	Hold	11,947	–	–	﹤0.01%	2236
2018 Q3	$198K	Hold	11,947	–	–	﹤0.01%	2084
2018 Q2	$192K	Hold	11,947	–	–	﹤0.01%	1940
2018 Q1	$183K	Hold	11,947	–	–	﹤0.01%	1939
2017 Q4	$186K	Buy	+11,947	New	+$160K	﹤0.01%	1969

MetLife Investment Management's STML Position: Q2 2020 in Review

MetLife Investment Management sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 18,471 shares — an estimated $89.4K sold.

MetLife Investment Management first reported a position in STML in Q4 2017 and held it in 10 quarters. The position peaked at $283K in Q2 2019. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.

MetLife Investment Management reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
MetLife Investment Management sold 18,471 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $89.4K.
MetLife Investment Management first reported a position in Stemline Therapeutics, Inc. in Q4 2017 and held it in 10 quarters.
MetLife Investment Management's Stemline Therapeutics, Inc. position peaked at $283K in Q2 2019.
0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.

Based on MetLife Investment Management's 13F filing for Q2 2020, filed 14 Aug 2020.